ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC)

被引：2
|
作者：
Forster, M. [1 ]
Mendes, R. [1 ]
Urbano, T. Guerrero [2 ]
Evans, M. [3 ,4 ]
Lei, M. [2 ]
Spanswick, V. [5 ]
Miles, E. [6 ]
Simoes, R. [6 ]
Wheeler, G. [7 ]
Forsyth, S. [8 ]
White, L. [8 ]
机构：
[1] Univ Coll London Hosp, Dept Oncol, London, England
[2] Guys & St Thomas Hosp, Dept Oncol, London, England
[3] Univ Hosp Wales UHW, Velindre Canc Ctr, Cardiff, Wales
[4] Vale Univ Hlth Board CVUHB, NHS Wales, Cardiff, Wales
[5] UCL Canc Inst, UCL ECMC GCLP Facil, London, England
[6] Mt Vernon Canc Ctr, Radiotherapy Trials Qual Assurance RTTQA Grp, Radiotherapy Phys, Northwood, Middx, England
[7] Imperial Coll London, Imperial Clin Trials Unit, London, England
[8] UCL, CR UK & UCL Canc Trials Ctr, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1276
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
866P
引用
收藏
页码：S789 / S790
页数：2
相关论文
共 50 条
  • [31] Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin
    Thana Patimarattananan
    Arkom Nongnuch
    Poompis Pattaranutaporn
    Nattawut Unwanatham
    Chuleeporn Jiarpinitnun
    Nuttapong Ngamphaiboon
    Supportive Care in Cancer, 2021, 29 : 877 - 887
  • [32] PHASE I/II STUDY OF ERLOTINIB COMBINED WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Herchenhorn, Daniel
    Dias, Fernando L.
    Viegas, Celia M. P.
    Federico, Miriam H.
    Araujo, Carlos Manoel M.
    Small, Isabelle
    Bezerra, Marcos
    Fontao, Karina
    Knust, Renata E.
    Ferreira, Carlos G.
    Martins, Renato G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 696 - 702
  • [33] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Goshi Nishimura
    Takahide Taguchi
    Masahiro Takahashi
    Osamu Shiono
    Masanori Komatsu
    Daisuke Sano
    Kenichiro Yabuki
    Yasuhiro Arai
    Hideaki Takahashi
    Masaharu Hata
    Nobuhiko Oridate
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1315 - 1319
  • [34] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Nishimura, Goshi
    Taguchi, Takahide
    Takahashi, Masahiro
    Shiono, Osamu
    Komatsu, Masanori
    Sano, Daisuke
    Yabuki, Kenichiro
    Arai, Yasuhiro
    Takahashi, Hideaki
    Hata, Masaharu
    Oridate, Nobuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1315 - 1319
  • [35] Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
    Mak, Milena Perez
    Pasini, Fatima Solange
    Diao, Lixia
    Teixeira Garcia, Fabyane O.
    Takahashi, Tiago Kenji
    Nakazoto, Denyei
    Martins, Renata Eiras
    Almeida, Cristiane Maria
    Vamondes Kulcsar, Marco Aurelio
    Lamounier, Valdelania Aparecida
    Nunes, Emily Montosa
    de Souza, Isabela Cristina
    Taveira Garcia, Marcio Ricardo
    Amadio, Alex Vieira
    Siqueira, Sheila Aparecida C.
    Longo Snitcovsky, Igor Moyses
    Sichero, Laura
    Wang, Jing
    de Castro Jr, Gilberto
    ECANCERMEDICALSCIENCE, 2020, 14
  • [36] Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Tahara, Makoto
    Minami, Hironobu
    Kawashima, Mitsuhiko
    Kawada, Kenji
    Mukai, Hirofumi
    Sakuraba, Minoru
    Matsuura, Kazuto
    Ogino, Takashi
    Hayashi, Ryuichi
    Ohtsu, Atsushi
    CANCER SCIENCE, 2011, 102 (02) : 419 - 424
  • [37] A phase I study of metformin in combination with cisplatin and radiation in locally advanced head and neck squamous cell carcinoma.
    Wise-Draper, Trisha Michel
    Takiar, Vinita
    Mierzwa, Michelle Lynn
    Huth, Bradley Joseph
    Redmond, Kevin P.
    Barrett, William
    Qualtieri, Julianne
    Xie, Changchun
    Morris, John Charles
    Gutkind, J. Silvio
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma
    Papadimitrakopoulou, Vasiliki A.
    Frank, Steven J.
    Cohen, Ezra W.
    Hirsch, Fred R.
    Myers, Jeffrey N.
    Heymach, John V.
    Lin, Heather
    Tran, Hai T.
    Chen, Changhu R.
    Jimeno, Antonio
    Nedzi, Lucien
    Vasselli, Joseph R.
    Lowe, Elizabeth S.
    Raben, David
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (03): : 439 - 447
  • [39] Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy
    Wang, Yan-Yang
    Bai, Zhou-Lan
    He, Jian-Li
    Yang, Yan
    Zhao, Ren
    Hai, Ping
    Zhe, Hong
    DISEASE MARKERS, 2016, 2016
  • [40] Compliance of elderly head and neck squamous cell carcinoma (HNSCC) patients (pts) with concurrent chemoradiotherapy (CRT) in cetuximab versus cisplatin.
    Kazan, Eyad
    Kleihneny, Tiffanie
    Sakek, Nacera
    Thomas, Alice
    Milian, Lucia
    Edel, Magali
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345